SOURCE: PharmaVigilant

PharmaVigilant

April 27, 2010 09:46 ET

PharmaVigilant Supports Multiple Clinical Trials for Supernus

Supernus Pharmaceuticals Selects PharmaVigilant's Complete Clinical Trial Technology Suite to Support Two International CNS Studies

WESTBOROUGH, MA--(Marketwire - April 27, 2010) -  PharmaVigilant, a clinical trial technology provider, has been selected by Supernus Pharmaceuticals to support two studies focused on the development of new drugs to treat central nervous system diseases. Supernus will implement PharmaVigilant's InSpire EDC solution, I-Vault, I-Warehouse and Remote Source Document Verification (rSDV) to support the preparation, conduct and closeout of two trials that are currently in progress.

According to Paolo Baroldi, M.D., Ph.D., Chief Medical Officer at Supernus Pharmaceuticals. Inc., "We were attracted to PharmaVigilant because it offers a cost effective solution that will benefit us in terms of speed, integration and efficiency. PharmaVigilant's integration with CROs will also allow us greater flexibility and accessibility to our data, making the entire process easier to manage at every level."

"Partnering with Supernus Pharmaceuticals has been an ideal opportunity for us to showcase the international capabilities of our technology to deliver on a rapid timeline while providing a completely integrated software solution that offers full visibility into all aspects of study conduct, across multiple countries," said James DeSanti, Founder and Chief Executive Officer, PharmaVigilant. "I am confident that through this partnership, Supernus will continue to deliver successfully on their dedication to improving the lives of people suffering from diseases of the central nervous system."

PharmaVigilant's technology offers sponsors complete flexibility and transparency of their data. With this technology, Supernus gains total control of all data and documents including source documents across continents and across clinical services providers. PharmaVigilant offers a full suite of clinical trial technology offerings including Electronic Data Capture (EDC), data warehousing, study building (I-Builder 2.0), Electronic Trial Master File System (eTMF), Remote Source Document Verification (rSDV), study administration and an automated site payment system. PharmaVigilant focuses on Phase I-IV clinical trials, registries and other post-marketing studies. The technology has supported more than 200,000 patients in 14 countries across North America, Europe, Asia and Australia and continues to expand rapidly.

About PharmaVigilant:

Based in Westborough, Mass., PharmaVigilant is a technology company founded in 2005 to streamline the clinical trial process for biopharmaceutical companies. Its fully integrated suite of patient-based technology automates the collection and management of clinical trial data and most importantly puts that data in the sponsors' hands when and how they want it. Sponsors rely on PharmaVigilant to ease the regulatory and FDA submission and approval process and ultimately go to market more quickly with top quality drugs. For more information, visit www.pharmavigilant.com.

Contact Information